Chemical Identity

Mechanism of Action

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a partial sequence of body protection compound isolated from human gastric juice. Its principal mechanism involves modulation of the nitric oxide (NO) signaling system. Research shows BPC-157 activates endothelial nitric oxide synthase (eNOS) through interaction with the Src-Caveolin-1 complex, facilitating NO-mediated vasodilation and endothelial barrier stabilization in experimental wound models.

At the receptor level, BPC-157 upregulates vascular endothelial growth factor receptor 2 (VEGFR2) expression on endothelial cells, driving angiogenic responses and promoting capillary network formation in tissue-defect models. Parallel studies implicate the FAK-paxillin signaling axis, governing cytoskeletal reorganization, cell migration, and ECM remodeling — processes central to fibroblast recruitment and wound scaffold assembly.

BPC-157 also demonstrates interactions with central dopaminergic and serotonergic systems in CNS-focused in vivo research. Its proline-rich linear structure, lacking disulfide bonds, confers conformational rigidity and resistance to enzymatic degradation in aqueous research environments.

Research Applications

• Fibroblast proliferation and ECM remodeling studies (in vitro wound models)
• Angiogenesis and VEGFR2-mediated endothelial cell growth research
• Gastrointestinal mucosal integrity and enteric nervous system investigations
• Tendon-to-bone healing and connective tissue repair models
• Nitric oxide pathway and eNOS/Src-Caveolin-1 signaling studies
• Dopaminergic and GABAergic neurotransmission research (in vivo rodent models)
• Anti-inflammatory cytokine modulation studies (NF-κB, TNF-α, IL-6)

Peer-Reviewed References

1. Sikiric P, et al. Brain-gut Axis and Pentadecapeptide BPC 157. Curr Neuropharmacol. 2016;14(8):745–760.
2. Vukojević J, et al. Rat inferior caval vein ligature and BPC 157. Oncotarget. 2018;9(18):14480–14496.
3. Gwyer D, et al. BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153–159.
4. Sikiric P, et al. Stable Gastric Pentadecapeptide BPC 157 in Clinical Trials. Pharmaceuticals. 2022;15(3):324.
5. Chang CH, et al. The promoting effect of BPC 157 on tendon healing. J Appl Physiol. 2011;110(3):774–780.

Testing & Supply Specifications

Every Blueprint Labs batch is independently verified by third-party analytical laboratories prior to release. Identity and purity confirmed via HPLC and mass spectrometry. Full batch records maintained for chain-of-custody traceability.

📄 View Certificate of Analysis